US 12,331,111 B2
Anti-MS4A4A antibodies and methods of use thereof
Philip Kong, San Francisco, CA (US); Herve Rhinn, San Francisco, CA (US); Tina Schwabe, San Francisco, CA (US); Angie Yee, San Francisco, CA (US); Ilaria Tassi, San Francisco, CA (US); Muhammad Abbas Alhawagri, San Francisco, CA (US); and Arnon Rosenthal, Woodside, CA (US)
Assigned to Alector LLC, South San Francisco, CA (US)
Filed by Alector LLC, South San Francisco, CA (US)
Filed on Aug. 19, 2022, as Appl. No. 17/821,006.
Application 17/821,006 is a division of application No. 16/965,676, granted, now 11,472,874, previously published as PCT/US2019/016156, filed on Jan. 31, 2019.
Claims priority of provisional application 62/783,096, filed on Dec. 20, 2018.
Claims priority of provisional application 62/624,600, filed on Jan. 31, 2018.
Prior Publication US 2023/0126400 A1, Apr. 27, 2023
Int. Cl. C07K 16/18 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/28 (2013.01) [C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/71 (2013.01)] 24 Claims
OG exemplary drawing
 
1. A method of treating an individual having Alzheimer's disease, late onset Alzheimer's disease, or cognitive impairment, the method comprising administering to an individual in need thereof a therapeutically effective amount of an isolated antibody that binds to human MS4A4A, wherein the antibody comprises a heavy chain variable region and a light chain variable region,
wherein the heavy chain variable region and the light chain variable region comprise an HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 comprising the amino acid sequences selected from the group consisting of SEQ ID NOs: 4, 20, 38, 56, 75, and 86, respectively; SEQ ID NOs: 5, 21, 39, 57, 76, and 87, respectively; SEQ ID NOs: 6, 22, 40, 58, 76, and 88, respectively; SEQ ID NOs: 7, 23, 41, 59, 77, and 89, respectively; SEQ ID NOs: 8, 24, 42, 60, 78, and 90, respectively; SEQ ID NOs: 9, 25, 43, 61, 76, and 91, respectively; SEQ ID NOs: 10, 26, 44, 62, 79, and 93, respectively; SEQ ID NOs: 7, 27, 45, 63, 77, and 89, respectively; SEQ ID NOs: 7, 28, 46, 64, 77, and 89, respectively; SEQ ID NOs: 11, 29, 47, 65, 80, and 93, respectively; SEQ ID NOs: 12, 27, 45, 66, 77, and 89, respectively; SEQ ID NOs: 13, 30, 48, 67, 76, and 94, respectively; SEQ ID NOs: 14, 31, 49, 68, 81, and 95, respectively; SEQ ID NOs: 16, 33, 51, 70, 77, and 97, respectively; SEQ ID NOs: 17, 34, 52, 71, 83, and 98, respectively; SEQ ID NOs: 19, 36, 54, 73, 84, and 100, respectively; SEQ ID NOs: 7, 37, 55, 74, 85, and 89, respectively; SEQ ID NOs: 142, 154, 168, 183, 197, and 210 respectively; SEQ ID NOs: 144, 156, 170, 185, 199, and 212, respectively; SEQ ID NOs: 144, 157, 171, 186, 81, and 213, respectively; SEQ ID NOs: 145, 158, 172, 186, 81, and 214, respectively; SEQ ID NOs: 146, 159, 173, 187, 200, and 215, respectively; SEQ ID NOs: 147, 160, 174, 188, 201, and 216, respectively; SEQ ID NOs: 148, 161, 175, 189, 202, and 217, respectively; SEQ ID NOs: 149, 162, 176, 190, 203, and 218, respectively; SEQ ID NOs: 150, 163, 177, 191, 204, and 219, respectively; SEQ ID NOs: 151, 164, 178, 192, 205, and 220, respectively; SEQ ID NOs: 147, 160, 179, 193, 206, and 221, respectively; SEQ ID NOs: 152, 165, 180, 194, 207, and 222, respectively; SEQ ID NOs: 153, 166, 181, 195, 208, and 223, respectively; SEQ ID NOs: 151, 167, 182, 196, 209, and 224, respectively; SEQ ID NOs: 304, 310, 316, 322, 328, and 334, respectively; SEQ ID NOs: 305, 311, 317, 323, 329, and 335, respectively; SEQ ID NOs: 306, 312, 318, 324, 330, and 336, respectively; SEQ ID NOs: 307, 313, 319, 325, 331, and 337, respectively; SEQ ID NOs: 308, 314, 320, 326, 332, and 338, respectively; SEQ ID NOs: 309, 315, 321, 327, 333, and 339, respectively; SEQ ID NOs: 15, 32, 50, 69, 82, and 96, respectively; SEQ ID NOs: 18, 35, 53, 72, 77, and 99, respectively; and SEQ ID NOs: 143, 155, 169, 184, 198, and 211, respectively.